Autres langues Neurocrine Biosciences, Inc.

Actions

NBIX

US64125C1099

Temps réel estimé Cboe BZX Autres places de cotation 15:49:37 19/04/2024			Varia. 5j.	Varia. 1 janv.
132,4 ^USD	-0,13 %		-0,75 %	+1,43 %

16/04	Sentia Medical Sciences Inc. et Neurocrine Biosciences, Inc. étendent leur collaboration de recherche pour découvrir de nouveaux peptides CRF	CI
08/04	NEUROCRINE BIOSCIENCES, INC. : Morgan Stanley optimiste sur le dossier	ZM

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Nxera Pharma's Neuro Drug NBI-1117568 Passed Preclinical Toxicity Test	17/04
Neurocrine Biosciences, Sentia Medical Sciences Extend Partnership on Prospective Drug Development	16/04
Sentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration to Discover Novel CRF Peptides	16/04
Sentia Medical Sciences Inc. and Neurocrine Biosciences, Inc. Extend Research Collaboration to Discover Novel CRF Peptides	16/04
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2024 Financial Results	10/04
Neurocrine Biosciences Doses First Patient in Phase 2 Depressive Disorder Study	03/04
Neurocrine Biosciences Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder	03/04
Neurocrine Biosciences, Inc. Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder	03/04
Neurocrine Biosciences Starts Phase 1 Trial of Investigational Neuropsychiatric Drug	28/03
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1065890, a Second-Generation VMAT2 Inhibitor, in Healthy Adults	28/03
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1065890, a Second-Generation VMAT2 Inhibitor, in Healthy Adults	28/03
Neurocrine Biosciences Insider Sold Shares Worth $5,576,710, According to a Recent SEC Filing	15/03
Neurocrine Biosciences Insider Sold Shares Worth $420,419, According to a Recent SEC Filing	15/03
Neurocrine Biosciences to Participate at Virtual Investor Conferences in March	11/03
Neurocrine Biosciences Insider Sold Shares Worth $922,632, According to a Recent SEC Filing	01/03
Neurocrine Biosciences Insider Sold Shares Worth $1,085,388, According to a Recent SEC Filing	01/03
Neurocrine Biosciences to Participate at Investor Conferences in March	27/02
Voyager Therapeutics Announces Selection of Gene Therapy Development Candidate for Friedreich's Ataxia in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment	27/02
Voyager Therapeutics, Inc. Announces Selection of Gene Therapy Development Candidate for Friedreich's Ataxia in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment	26/02
Neurocrine Biosciences Insider Sold Shares Worth $1,987,047, According to a Recent SEC Filing	22/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Neurocrine Biosciences, Inc.

Actions

NBIX

US64125C1099

Autres langues

Filtres